Navigation Links
HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
Date:9/28/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 28, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that clinical data for the HeartWare® Ventricular Assist System will be presented on Sunday, October 2, 2011 at the 25th EACTS Annual Meeting in Lisbon, Portugal.

A presentation by Mark S. Slaughter, M.D., entitled HeartWare®: Results of the ADVANCE Bridge to Transplant Trial, is scheduled for Sunday, October 2, 2011, at noon local time (7:00 a.m. U.S. Eastern Daylight Time) in Auditorium 1 of the Lisbon Congress Centre.  Dr. Slaughter, a principal investigator for HeartWare's ADVANCE trial, is Professor and Chief in the Division of Thoracic and Cardiovascular Surgery and Director of the Mechanical Assist Device and Heart Transplant Program at the University of Louisville.  The presentation will include clinical data from ADVANCE, as well as from the Continued Access Protocol for that study.

Investor Breakout Session and Webcast

Following the data presentation at EACTS, HeartWare management will host an investor breakout session with Dr. Slaughter, which will be available via audio webcast and conference call, at 2:00 p.m. local time (9:00 a.m. U.S. Eastern Daylight Time) on October 2, 2011 in Room 1.06 of the Lisbon Congress Centre.  

The audio from the meeting will be available to the public via webcast through the Company's website at (http://www.heartware.com/) by selecting "EACTS Investor Meeting" under the section titled "Corporate Presentations" on the home page.  A replay of the audio webcast will be available through the above weblink shortly following completion of the investor meeting. The audio for the meeting may also be accessed by dialing 1-800-215-2410 five minutes prior to the scheduled start time and referencing passcode 46162598.  For callers outside the United States, please dial +1-617-597-5410 and reference passcode 46162598.

Slides from the presentation at EACTS will be available following the presentation on the Company's International website (http://www.heartware.com) by selecting the International region, then Clinicians, then Clinical Trials.  

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol and is not yet commercially available.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
2. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
3. HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
4. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
5. HeartWare to Report Financial Results for Second Quarter of 2011
6. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
7. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
8. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
9. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
10. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
11. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017 Revenue Prospects by Product Type ... COPD) and Geography Respiratory Inhalers - our new study ... Respiratory Inhalers market heading? If you are involved in this sector ... shows you the potential revenues streams to 2027, assessing data, trends, ... ...
(Date:3/29/2017)... , March 29, 2017 Wound care devices ... healing of the wound. The industry mainly consists of ... for the treatment of wounds caused by mechanical, chemical, ... to diseases such as diabetes, skin related diseases, immunological ... Europe was the largest region in the ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino ... its network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo ... flail mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced ... retails normally at $29.97; for the remaining days of March, the price will be ... to a special price of just $10 (regular retail price $19.97). , The special ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
Breaking Medicine News(10 mins):